# Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)

> **NCT06450574** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Corporacion Parc Tauli** · enrollment: 106 (estimated)

## Conditions studied

- Rectal Cancer Stage I

## Interventions

- **DRUG:** Capecitabine (Xeloda)
- **RADIATION:** 50.4 Gy
- **PROCEDURE:** Transanal Endoscopic Microsurgery (TEM)
- **PROCEDURE:** Transanal Endoscopic Microsurgery

## Key facts

- **NCT ID:** NCT06450574
- **Lead sponsor:** Corporacion Parc Tauli
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-10
- **Primary completion:** 2026-10
- **Final completion:** 2027-10
- **Target enrollment:** 106 (ESTIMATED)
- **Last updated:** 2024-06-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06450574

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06450574, "Preoperative Chemoradiotherapy and Transanal Endoscopic Microsurgery Versus Ttransanal Endoscopic Microsurgery in T1 N0, M0 Rectal Cancer (TAUTEM-T1 Study)". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06450574. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*